Cidara Therapeutics, Inc. - Common Stock (NQ:CDTX)

221.03 +0.14 (+0.06%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Price and Volume

Volume	1,427,459
Open	220.85
Bid (Size)	220.21 (200)
Ask (Size)	221.49 (1,000)
Prev. Close	220.89
Today's Range	220.47 - 221.10
52wk Range	15.22 - 221.20
Shares Outstanding	49,506,268
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗

January 02, 2026

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

Via The Motley Fool

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Performance

YTD	N/A	N/A
1 Month	+0.0%	+0.0%
3 Month	+116.7%	+116.7%
6 Month	+357.6%	+357.6%
1 Year	+709.6%	+709.6%

More News

Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover ↗

November 17, 2025

Via Stocktwits

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

Via MarketMinute

Halper Sadeh LLC Encourages EB, KPLT, WBD, CDTX Shareholders to Contact the Firm to Discuss Their Rights

December 18, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Halper Sadeh LLC Encourages CADE, MRSN, CDTX Shareholders to Contact the Firm to Discuss Their Rights

December 10, 2025

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mersana Therapeutics, Inc. (Nasdaq - MRSN), Cidara Therapeutics, Inc. (Nasdaq - CDTX), Cadence Bank (NYSE – CADE)

December 10, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights

December 08, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy? ↗

December 07, 2025

Via The Motley Fool

Is This Pharmaceutical Giant a Buy After a Major Acquisition? ↗

December 05, 2025

Via The Motley Fool

3 Non-AI Stocks to Buy: MRK, UPS, CVX ↗

November 30, 2025

Via The Motley Fool

Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%? ↗

November 29, 2025

Via The Motley Fool

Halper Sadeh LLC Encourages AXTA, SEMR, CDTX Shareholders to Contact the Firm to Discuss Their Rights

November 27, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Halper Sadeh LLC Encourages THS, CDTX, SPNS Shareholders to Contact the Firm to Discuss Their Rights

November 22, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗

November 20, 2025

Via The Motley Fool

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗

November 20, 2025

Via The Motley Fool

Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs? ↗

November 20, 2025

Via The Motley Fool

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗

November 20, 2025

Via The Motley Fool

Biotech Stock Gets Booted in Latest Fund Update ↗

November 19, 2025

Via The Motley Fool

Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗

November 19, 2025

Via The Motley Fool

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything ↗

November 18, 2025

Via MarketBeat

Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗

November 18, 2025

Via The Motley Fool

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗

November 17, 2025

Via The Motley Fool

Top 2 Health Care Stocks That May Fall Off A Cliff This Month ↗

November 17, 2025

Via Benzinga

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX

November 16, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Frequently Asked Questions

Is Cidara Therapeutics, Inc. - Common Stock publicly traded?

Yes, Cidara Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Cidara Therapeutics, Inc. - Common Stock trade on?

Cidara Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cidara Therapeutics, Inc. - Common Stock?

The ticker symbol for Cidara Therapeutics, Inc. - Common Stock is CDTX on the Nasdaq Stock Market

What is the current price of Cidara Therapeutics, Inc. - Common Stock?

The current price of Cidara Therapeutics, Inc. - Common Stock is 221.03

When was Cidara Therapeutics, Inc. - Common Stock last traded?

The last trade of Cidara Therapeutics, Inc. - Common Stock was at 01/02/26 04:00 PM ET

What is the market capitalization of Cidara Therapeutics, Inc. - Common Stock?

The market capitalization of Cidara Therapeutics, Inc. - Common Stock is 10.94B

How many shares of Cidara Therapeutics, Inc. - Common Stock are outstanding?

Cidara Therapeutics, Inc. - Common Stock has 11B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.